The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I suspect there is a single large seller in the background, repeatedly using the U/T to offload at the end of each day, which gives the MM’s a new inventory of stock to pass on each time. Sooner or later someone will come in for the lot, so the positive trigger is likely to be a sudden spike in volume. Why this holder is selling is anyone’s guess - they had all the nous to buy SYNT at multiples of the current price ie not much… FM’s are very overrated :)
Or perhaps just somebody who understands that the price you pay is important to an investment decision, candidinvestor? The market already knows all your consensual points, which basically amount to - SYNT has debt, interest rates have gone up, the economy isn’t great… which of these points do you think the market isn’t already aware of? ..lol.. and the relevant exercise is to go back over the 35 years, identify periods where valuation and sentiment are heavily depressed, and work out what the ensuing return is over a 3/5 year time horizon… here’s some of your homework done for you: nov ‘90 to nov ‘93 = 300%+, sept ‘00 to sept ‘03 = 100%+, jan 09 to jan ‘12 = 500%+… it’s about price, valuation, timing etc… I wouldn’t be interested here except the valuation is low and sentiment depressed, and crucially the most consensual investors are reeling off consensual commentary as if they are the only ones “in the know”… ATB :)
I can read the name “candidinvestor”…. But having read the post I suspect “consensusinvestor” may be more appropriate. It is naive to believe that your highly consensual points represent “news” to the market. I don’t know whether SYNT is heading to 50p or 90p over the next few weeks/months - but then I don’t think any sensible person can confidently have a view on that. But on a 3 year view - a sensible time frame - I believe the shares will be £2+… Short term voting machine, long term weighing machine.. ATB
I notice the enterprise value is now about what it was in 2018/19 prior to the Omnova and Eastman acquisitions….. you are now getting both for free … combined purchases added £1Bn+ revenues and not a bad mix either… yes they have divested laminates but they also operationally generated hundreds of millions in equity during the covid boom phase… atb
Thank you :)
Actually I sold a few hundred thousand this morning at the bid, no problem. Still leaves me a couple of million shares. The amusing thing 4corners is you are here quite regularly, presumably you know something about the story, yet you completely missed it… whoopsy :)
Dancing over an illiquid rally?! Yes, I’m happy that I can sell my shares 60%+ higher than I could a few weeks ago. How very strange of me. Easy to spot the ones who can’t sell 60%+ higher, cos they failed to buy.. :)
Indeed mcatee.. complete bllk5!!.. and well done being the only poster here to call it right.. “4 Corners!!! WTF!!!! Your July target price was way off - a complete load of b11k5!!!”
WTP - i am only posting this in response to your previous message. I did not think the update was positive for moditope, nor did I claim it was. I sold most of my holding months before the RNS. I made my reasons clear -“In my opinion and experience, by reporting on 14 patients at scan 1, they have created a precedent. And if they don’t maintain consistency by reporting after scan 2, then investors will legitimately start to question why…” (April 26th)
I suspect the reason they combined the update into one RNS is because they thought the moditope data would not be received well, so they wanted to nest it with more positive news. You have to wonder additionally why - given moditope has been LD’s favourite - the moditope data plays second place to scib… all is not lost for moditope, but I can see why the shares have fallen… IMO
Confusion reigns! The Feb release suggests that 5 non ovarian patients had been dosed.. “To date, 23 patients have been vaccinated, 18 with HGSOC, two with TNBC, two with SCCHN and one with RCC, with 55 doses being administered in total.”